743 IDEXX Laboratories, Inc. $IDXX Shares Sold by Lido Advisors LLC

Lido Advisors LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 19.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,141 shares of the company’s stock after selling 743 shares during the quarter. Lido Advisors LLC’s holdings in IDEXX Laboratories were worth $1,640,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Arlington Trust Co LLC raised its position in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Bell Investment Advisors Inc lifted its stake in IDEXX Laboratories by 45.5% during the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after purchasing an additional 20 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its stake in IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock worth $67,000 after purchasing an additional 21 shares during the last quarter. Valeo Financial Advisors LLC lifted its stake in IDEXX Laboratories by 6.4% during the second quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock worth $202,000 after purchasing an additional 23 shares during the last quarter. Finally, Meeder Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 1.3% in the first quarter. Meeder Advisory Services Inc. now owns 1,896 shares of the company’s stock worth $1,066,000 after purchasing an additional 25 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on IDXX shares. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. Jefferies Financial Group dropped their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a report on Tuesday, October 20th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 price target for the company. Finally, Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.

Check Out Our Latest Stock Report on IDXX

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $704.23 on Monday. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average of $562.41 and a 200-day moving average of $573.52. The firm has a market capitalization of $55.49 billion, a PE ratio of 47.49 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the business posted $3.22 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Insider Activity

In other IDEXX Laboratories news, Director Daniel M. Junius sold 1,200 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total value of $844,884.00. Following the sale, the director directly owned 2,361 shares in the company, valued at approximately $1,662,309.27. This trade represents a 33.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Lane sold 3,979 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $688.64, for a total value of $2,740,098.56. Following the completion of the sale, the executive vice president owned 4,076 shares in the company, valued at $2,806,896.64. The trade was a 49.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,428 shares of company stock worth $28,567,934 over the last 90 days. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.